Navigation Links
Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
Date:12/1/2008

SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) announced today the receipt of a $1.0 million milestone payment from Merck & Co., Inc. based on Merck's planned initiation of a Phase I clinical trial of an investigational plasmid DNA (pDNA) cancer vaccine. The candidate vaccine is based on Vical's DNA gene delivery technology and encodes human telomerase reverse transcriptase (hTERT). hTERT is the subject of separate license agreement.

"The breadth of applications for Vical's gene delivery technology continues to grow, and now encompasses vaccine candidates against infectious diseases and cancer, cancer immunotherapies, and gene-based angiogenesis for cardiovascular diseases," said Vijay B. Samant, Vical's President and Chief Executive Officer. "We are pleased that our long-standing partner Merck is expanding to a second clinical-stage evaluation of our technology in the cancer area."

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether Merck will complete the Phase I clinical trial of its cancer vaccine; whether genes encoding hTERT will trigger immune responses against cancer cells; whether the cancer vaccine will be shown to be safe and effective in clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

    Contact:  Alan R. Engbring
    (858) 646-1127

Website: www.vical.com


'/>"/>
SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... A new Transparency Market Research report states ... at US$0.53 bn in 2013 and is predicted to touch US$2.38 ... 2014 and 2022. The title of the report is "Non-invasive Prenatal ... Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred to as ...
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in ... medical device technologies. BCC Research reveals in its new report ... region, should see strong growth due to rising government healthcare spending, ... Continue Reading ... ...
(Date:1/23/2017)... January 23, 2017 The global  anxiety disorders and depression ... 2025. The rising incidence of depression worldwide is anticipated to drive the market ... in the declining demand for antidepressants in the recent years. ... ... View Research Logo ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... ... science companies, has achieved ISO 17100:2015 certification following a comprehensive audit performed ... the globally recognized standard that establishes guidance for critical processes within translation, ...
(Date:1/23/2017)... ... January 23, 2017 , ... Ultimate Medical Academy today ... to be held March 23-25, 2017 in Tampa, and reminded educators and education ... keynote speakers include Dr. Michelle R. Weise, executive director of the Sandbox Collaborative, ...
(Date:1/23/2017)... ... January 23, 2017 , ... DMG Productions is ... Ed Begley, Jr., scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , ... in 2008 to address the limitations of fatigue monitoring technologies within the mining ...
(Date:1/23/2017)... IL (PRWEB) , ... January 23, 2017 , ... ... first-quality education and high-level training standards for healthcare treatment providers who treat the ... to its Presidents Council. , The Presidents Council consists of the leading ...
(Date:1/23/2017)... ... January 23, 2017 , ... Wooden and plastic balance boards have been around since at ... Kumo Board is the first and only balance board to use a patent-pending ... and rigid at the same time as well as skill-level adjustable for all ages and ...
Breaking Medicine News(10 mins):